4.5 Review

The neurological manifestations of acute liver failure

Journal

NEUROCHEMISTRY INTERNATIONAL
Volume 60, Issue 7, Pages 662-671

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuint.2011.10.006

Keywords

Acute liver failure; Neurology; Ammonia; Hepatic encephalopathy; Brain edema; Intracranial pressure; Cerebral blood flow

Funding

  1. U.K. Department of Health HEFCE Clinical Senior Lectureship

Ask authors/readers for more resources

Acute liver failure is a disorder which impacts on multiple organ systems and results from hepatocellular necrosis in a patient with no previous history of chronic liver disease. It typically culminates in the development of liver dysfunction, coagulopathy and encephalopathy, and is associated with high mortality in poor prognostic groups. In acute liver failure, some patients may develop cerebral edema and increased intracranial pressure although recent data suggest that intracranial hypertension is less frequent than previously described, complicating 29% of acute cases who have proceeded to grade 3/4 coma. Neurological manifestations are primarily underpinned by the development of brain edema. The onset of encephalopathy can be rapid and dramatic with the development of asterixis, delirium, hyperreflexia, clonus, seizures, extensor posturing and coma. Ammonia plays a definitive role in the development of cytotoxic brain edema. Patients with acute liver failure have a marked propensity to develop renal insufficiency and hence impaired ammonia excretion. The incidence of both bacterial and fungal infection occurs in approximately one third of patients. The relationship between inflammation, as opposed to infection, and progression of encephalopathy is similar to that observed in chronic liver disease. Intracranial pressure monitoring is valuable in identifying surges in intracranial hypertension requiring intervention. Insertion of an intracranial bolt should be considered only in the subgroup of patients who have progressed to grade 4 coma. Risk factors for developing intracranial hypertension are those with hyperacute and acute etiologies, progression to grade 3/4 hepatic encephalopathy, those who develop pupillary abnormalities (dilated pupils, sluggishly responsive to light) or seizures, have systemic inflammation, an arterial ammonia >150 mu mol/L, hyponatremia, and those in receipt of vasopressor support. Strategies employed in patients with established encephalopathy (grade 3/4) aim to maintain freedom from infection/inflammatory milieu, provide adequate sedation, and correct hypo-osmolality. (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

Vishal C. Patel, Sunjae Lee, Mark J. W. McPhail, Kevin Da Silva, Susie Guilly, Ane Zamalloa, Elizabeth Witherden, Sidsel Stoy, Godhev Kumar Manakkat Vijay, Nicolas Pons, Nathalie Galleron, Xaiohong Huang, Selin Gencer, Muireann Coen, Thomas Henry Tranah, Julia Alexis Wendon, Kenneth D. Bruce, Emmanuelle Le Chatelier, Stanislav Dusko Ehrlich, Lindsey Ann Edwards, Saeed Shoaie, Debbie Lindsay Shawcross

Summary: Rifaximin-alpha can alleviate hepatic encephalopathy and reduce the likelihood of infection by reducing systemic inflammation and promoting gut barrier repair.

JOURNAL OF HEPATOLOGY (2022)

Review Gastroenterology & Hepatology

Implications and Management of Cirrhosis-Associated Immune Dysfunction Before and After Liver Transplantation

Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross

Summary: CAID is a condition characterized by immune dysfunction in patients with cirrhosis, resulting in impaired innate and adaptive immune responses. This dysfunction is driven by gut-barrier dysfunction and deficits in microbial compartmentalization, leading to systemic inflammation and exhaustion of immune cells. Understanding and addressing these immune dysregulations are crucial for improving patient outcomes and preventing complications in cirrhosis.

LIVER TRANSPLANTATION (2022)

Editorial Material Gastroenterology & Hepatology

Statins: A Panacea to Reduce Mortality in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma?

Debbie L. Shawcross, Abid Suddle

LIVER TRANSPLANTATION (2022)

Review Gastroenterology & Hepatology

Management of Multidrug-Resistant Infections in Cirrhosis

Charles E. Gallaher, Debbie L. Shawcross

Summary: Antimicrobial resistance is a major threat to global health, and its indiscriminate use has led to the emergence of multidrug-resistant bacteria. Patients with cirrhosis are at a higher risk of multidrug-resistant organism (MDRO) infections due to their frequent use of antibiotics, invasive procedures, and recurrent hospitalizations. This review explores the vulnerability of cirrhosis patients to MDRO infections, the impact of bacterial infections on disease progression, prevalence of MDROs, outcomes, fungal infections, antibiotics efficacy, and management approaches.

SEMINARS IN LIVER DISEASE (2022)

Review Gastroenterology & Hepatology

Gut-derived systemic inflammation as a driver of depression in chronic liver disease

Victoria T. Kronsten, Thomas H. Tranah, Carmine Pariante, Debbie L. Shawcross

Summary: Depression and chronic liver disease (CLD) are significant contributors to disability, morbidity, and mortality. The high prevalence of depression in CLD patients may be linked to systemic inflammation, gut dysbiosis, and a dysfunctional gut-liver-brain axis.

JOURNAL OF HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH)

Cesar Jimenez, Meritxell Ventura-Cots, Margarita Sala, Margalida Calafat, Montserrat Garcia-Retortillo, Isabel Cirera, Nuria Canete, German Soriano, Maria Poca, Macarena Simon-Talero, Jose Altamirano, Michael Lucey, Guadalupe Garcia-Tsao, Robert S. Brown, Robert F. Schwabe, Elizabeth C. Verna, Bernd Schnabl, Francisco Bosques-Padilla, Philippe Mathurin, Juan Caballeria, Alexandre Louvet, Debbie L. Shawcross, Juan G. Abraldes, Joan Genesca, Ramon Bataller, Victor Vargas

Summary: Rifaximin as an adjuvant treatment for alcoholic hepatitis can significantly reduce the number of infections and clinical complications, contributing to a lower incidence of acute-on-chronic liver failure and mortality.

LIVER INTERNATIONAL (2022)

Letter Gastroenterology & Hepatology

Reply to: Possible link between higher ammonia levels, non- alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic kidney disease?

Thomas H. Tranah, Maria-Pilar Ballester, Juan Antonio Carbonell-Asins, Rajiv Jalan, Debbie L. Shawcross

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines on the management of hepatic encephalopathyq

Sara Montagnese, Pierre-Emmanuel Rautou, Manuel Romero-Gomez, Fin Stolze Larsen, Debbie L. Shawcross, Dominique Thabut, Hendrik Vilstrup, Karin Weissenborn

Summary: The EASL Clinical Practice Guidelines on the management of hepatic encephalopathy provide evidence-based answers to questions about its definition, diagnosis, differential diagnosis, and treatment. However, it does not cover the pathophysiology of hepatic encephalopathy or all available treatment options.

JOURNAL OF HEPATOLOGY (2022)

Letter Gastroenterology & Hepatology

Reply to: Ammonia and prognosis of cirrhosis: A new perspective for identifying high risk patients

Thomas H. Tranah, Maria-Pilar Ballester, Juan Antonio Carbonell-Asins, Rajiv Jalan, Debbie L. Shawcross

JOURNAL OF HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Reply to: Ammonia - an old friend with a new area of application

Thomas H. Tranah, Maria-Pilar Ballester, Juan Antonio Carbonell-Asins, Rajiv Jalan, Debbie L. Shawcross

JOURNAL OF HEPATOLOGY (2023)

Editorial Material Gastroenterology & Hepatology

Let's Have Some Clarity on Academic Parity

Debbie L. Shawcross, Florence Wong

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)

Richard J. Aspinall, Mark Hudson, Stephen D. Ryder, Paul Richardson, Elizabeth Farrington, Mark Wright, Robert T. Przemioslo, Francisco Perez, Melanie Kent, Roland Henrar, Joe Hickey, Debbie L. Shawcross

Summary: In clinical practice in the UK, the use of RFX in patients with HE was associated with a 35% survival rate, high treatment adherence, 76% transplant-free survival rate, minimal healthcare resource utilization, and low rates of complications at 5 years post-initiation.

FRONTLINE GASTROENTEROLOGY (2023)

Editorial Material Gastroenterology & Hepatology

Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy

Debbie L. Shawcross, Dominique Thabut, Piero Amodio

JOURNAL OF HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Reply to: Ammonia - an old friend with a new area of application

Thomas H. Tranah, Maria-Pilar Ballester, Juan Antonio Carbonell-Asins, Rajiv Jalan, Debbie L. Shawcross

JOURNAL OF HEPATOLOGY (2023)

Review Infectious Diseases

Modulation of the Gut Microbiota to Control Antimicrobial Resistance (AMR)-A Narrative Review with a Focus on Faecal Microbiota Transplantation (FMT)

Blair Merrick, Chrysi Sergaki, Lindsey Edwards, David L. Moyes, Michael Kertanegara, Desiree Prossomariti, Debbie L. Shawcross, Simon D. Goldenberg

Summary: Antimicrobial resistance (AMR) presents a significant burden to the global healthcare system, particularly in Gram-negative organisms such as extended-spectrum beta-lactamase and carbapenemase-producing Enterobacterales (ESBL and CPE). These pathogens have limited treatment options, leading to poor clinical outcomes. Manipulating the gut microbiota through various methods, including diet, probiotics, bacteriophages, and fecal microbiota transplantation (FMT), can effectively restore colonization resistance and limit the spread of AMR organisms.

INFECTIOUS DISEASE REPORTS (2023)

Article Biochemistry & Molecular Biology

Interleukin-33 has the protective effect on oligodendrocytes against impairment induced by cuprizone intoxication

Hui-Ting Huang, Shun-Fen Tzeng

Summary: Our study demonstrates the role of interleukin-33 (IL-33) in a demyelinating mouse model induced by cuprizone (CPZ), showing that IL-33 can alleviate the reduction of APC+ OLs and the decline of IL-33 levels in the corpus callosum, and promote the expression of myelin basic protein (MBP).

NEUROCHEMISTRY INTERNATIONAL (2024)